Concepts (120)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Blood Component Removal | 3 | 2023 | 35 | 1.200 |
Why?
|
| Graft vs Host Disease | 6 | 2023 | 621 | 1.180 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 8 | 2023 | 1192 | 1.050 |
Why?
|
| Rituximab | 3 | 2020 | 166 | 0.890 |
Why?
|
| Peripheral Blood Stem Cells | 1 | 2023 | 1 | 0.840 |
Why?
|
| Bone Marrow Transplantation | 3 | 2022 | 617 | 0.800 |
Why?
|
| Bone Marrow | 1 | 2022 | 332 | 0.670 |
Why?
|
| Immunoglobulin G | 2 | 2020 | 803 | 0.660 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2020 | 64 | 0.640 |
Why?
|
| Enteropathy-Associated T-Cell Lymphoma | 1 | 2018 | 1 | 0.570 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2018 | 35 | 0.550 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 3 | 2023 | 25 | 0.440 |
Why?
|
| Antigens, CD34 | 3 | 2023 | 109 | 0.440 |
Why?
|
| Cyclophosphamide | 4 | 2023 | 425 | 0.400 |
Why?
|
| T-Lymphocytes, Regulatory | 4 | 2022 | 234 | 0.280 |
Why?
|
| Leukapheresis | 2 | 2023 | 14 | 0.260 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 1296 | 0.230 |
Why?
|
| Galactosylceramides | 2 | 2021 | 15 | 0.220 |
Why?
|
| Lymphopoiesis | 1 | 2023 | 9 | 0.200 |
Why?
|
| Heterocyclic Compounds | 1 | 2022 | 18 | 0.190 |
Why?
|
| Transplantation Conditioning | 2 | 2021 | 300 | 0.190 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 1305 | 0.190 |
Why?
|
| Leukocytes | 1 | 2023 | 209 | 0.190 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2023 | 554 | 0.180 |
Why?
|
| Interleukin-2 | 1 | 2022 | 241 | 0.180 |
Why?
|
| Neutropenia | 1 | 2023 | 205 | 0.180 |
Why?
|
| Erythrocytes | 1 | 2022 | 221 | 0.180 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2021 | 36 | 0.170 |
Why?
|
| Aminolevulinic Acid | 1 | 2020 | 9 | 0.170 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2020 | 31 | 0.170 |
Why?
|
| Immunoglobulin Class Switching | 1 | 2020 | 14 | 0.170 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2020 | 41 | 0.170 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2021 | 231 | 0.160 |
Why?
|
| Agammaglobulinemia | 1 | 2020 | 44 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 1348 | 0.160 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2020 | 127 | 0.150 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2020 | 225 | 0.150 |
Why?
|
| Retrospective Studies | 4 | 2023 | 17374 | 0.140 |
Why?
|
| Transplantation, Autologous | 1 | 2018 | 285 | 0.130 |
Why?
|
| Neprilysin | 1 | 2017 | 21 | 0.130 |
Why?
|
| CD5 Antigens | 1 | 2017 | 33 | 0.130 |
Why?
|
| Fatal Outcome | 1 | 2018 | 377 | 0.130 |
Why?
|
| Humans | 16 | 2023 | 132105 | 0.130 |
Why?
|
| Interleukin-6 | 1 | 2019 | 436 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 608 | 0.130 |
Why?
|
| Lung Transplantation | 1 | 2020 | 336 | 0.120 |
Why?
|
| Autoimmune Diseases | 1 | 2019 | 273 | 0.120 |
Why?
|
| Treatment Outcome | 4 | 2020 | 13017 | 0.120 |
Why?
|
| Immune Tolerance | 3 | 2022 | 153 | 0.120 |
Why?
|
| Salvage Therapy | 1 | 2018 | 201 | 0.120 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2017 | 153 | 0.110 |
Why?
|
| Aged | 4 | 2020 | 21413 | 0.100 |
Why?
|
| Mice | 4 | 2023 | 18566 | 0.100 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 5399 | 0.090 |
Why?
|
| Prognosis | 1 | 2020 | 5008 | 0.080 |
Why?
|
| Animals | 5 | 2023 | 34953 | 0.080 |
Why?
|
| Transplantation, Homologous | 2 | 2020 | 648 | 0.070 |
Why?
|
| B-Lymphocytes | 2 | 2021 | 543 | 0.070 |
Why?
|
| Postoperative Complications | 1 | 2020 | 3146 | 0.070 |
Why?
|
| Male | 5 | 2020 | 64918 | 0.070 |
Why?
|
| Hydroxyprostaglandin Dehydrogenases | 1 | 2005 | 1 | 0.060 |
Why?
|
| Prostaglandin H2 | 1 | 2005 | 4 | 0.060 |
Why?
|
| Trypanosoma brucei brucei | 1 | 2005 | 19 | 0.060 |
Why?
|
| Oxidoreductases | 1 | 2005 | 101 | 0.060 |
Why?
|
| Hydroxyethyl Starch Derivatives | 1 | 2023 | 8 | 0.050 |
Why?
|
| Granulocytes | 1 | 2023 | 69 | 0.050 |
Why?
|
| Molecular Weight | 1 | 2023 | 309 | 0.050 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2022 | 95 | 0.050 |
Why?
|
| Hematocrit | 1 | 2022 | 115 | 0.050 |
Why?
|
| Child | 1 | 2022 | 25758 | 0.050 |
Why?
|
| Female | 4 | 2021 | 70680 | 0.050 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2021 | 13 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2021 | 153 | 0.040 |
Why?
|
| Hypoxia | 1 | 2022 | 259 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 356 | 0.040 |
Why?
|
| Photosensitizing Agents | 1 | 2020 | 37 | 0.040 |
Why?
|
| Photochemotherapy | 1 | 2020 | 41 | 0.040 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2020 | 23 | 0.040 |
Why?
|
| Middle Aged | 1 | 2020 | 28936 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2021 | 520 | 0.040 |
Why?
|
| Dendritic Cells | 1 | 2021 | 448 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 1672 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2020 | 827 | 0.030 |
Why?
|
| Macrophages | 1 | 2021 | 693 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 816 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2021 | 1975 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1966 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2020 | 3698 | 0.020 |
Why?
|
| Lung | 1 | 2020 | 1556 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2021 | 4764 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 4694 | 0.020 |
Why?
|
| Young Adult | 1 | 2020 | 9940 | 0.020 |
Why?
|
| Circular Dichroism | 1 | 2005 | 80 | 0.010 |
Why?
|
| Citrates | 1 | 2005 | 24 | 0.010 |
Why?
|
| Models, Chemical | 1 | 2005 | 88 | 0.010 |
Why?
|
| Catalysis | 1 | 2005 | 138 | 0.010 |
Why?
|
| Tyrosine | 1 | 2005 | 148 | 0.010 |
Why?
|
| Protons | 1 | 2005 | 98 | 0.010 |
Why?
|
| Protein Structure, Secondary | 1 | 2005 | 246 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2005 | 309 | 0.010 |
Why?
|
| Catalytic Domain | 1 | 2005 | 180 | 0.010 |
Why?
|
| Ultraviolet Rays | 1 | 2005 | 202 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2005 | 454 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2005 | 448 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2005 | 652 | 0.010 |
Why?
|
| Crystallography, X-Ray | 1 | 2005 | 387 | 0.010 |
Why?
|
| Ligands | 1 | 2005 | 495 | 0.010 |
Why?
|
| Kinetics | 1 | 2005 | 1132 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2005 | 825 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2005 | 825 | 0.010 |
Why?
|
| Adolescent | 1 | 2020 | 20532 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2005 | 1118 | 0.010 |
Why?
|
| Swine | 1 | 2005 | 1197 | 0.010 |
Why?
|
| Evolution, Molecular | 1 | 2005 | 698 | 0.010 |
Why?
|
| Protein Binding | 1 | 2005 | 1735 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2005 | 2674 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2005 | 3778 | 0.010 |
Why?
|
| Adult | 1 | 2020 | 31557 | 0.010 |
Why?
|
| Rats | 1 | 2005 | 3612 | 0.010 |
Why?
|
| Mutation | 1 | 2005 | 6249 | 0.010 |
Why?
|